GlassScriptPhysician profile
Shahwali Arezo
NPI 1215975370
$3,920.12
in general payments reported to CMS, 2019-2025
29 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $626 · 2021: $345 · 2022: $500 · 2023: $314 · 2024: $605 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.46 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.44 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $282.39 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $254.20 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $199.14 | 2022-2025 | Dupixent |
| Exact Sciences Corporation | $179.95 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $176.00 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $138.56 | 2024 | Tremfya |
| Novo Nordisk INC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.65 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $87.64 | 2020-2023 | Linzess |
| Sumitomo Pharma America, INC. | $81.67 | 2025 | Gemtesa |
| Pfizer INC. | $76.74 | 2019-2025 | |
| Celltrion USA INC. | $60.17 | 2024-2025 | Vegzelma |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $45.32 | 2025 | Ibsrela |
| Lilly USA, LLC | $40.04 | 2025 | Omvoh |
| Alfasigma USA, INC. | $30.28 | 2020 | |
| Phathom Pharmaceuticals, INC. | $23.69 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $22.94 | 2019 | |
| Dova Pharmaceuticals | $22.51 | 2019 | |
| Olympus America INC. | $22.19 | 2019 | |
| Axonics, INC. | $20.64 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.92 | 2025 | Iqirvo |
| Concordia Pharmaceuticals INC. | $19.34 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.11 | 2023 | |
| Intercept Pharmaceuticals, INC. | $11.98 | 2019 | |
| Allergan, INC. | $11.61 | 2020 | |
| Merit Medical Systems INC | $9.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahwali Arezo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.